Calendario›REGN›REGN20423 · AURA-AD

REGN20423 · AURA-AD

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

Ensayo de REGENERON PHARMACEUTICALS, INC. en Voluntarios sanos · Dermatitis atopica.

Más ensayos de: Dermatitis atópica.

Fase

Fase 1

Estado

Reclutando pacientes

Participantes

144

previstos

Centros

1

Fin del objetivo primario

jun 2028

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en may 2026.

Qué mide

Occurrence of Treatment Emergent Adverse Events (TEAEs) (del registro, en inglés) (hasta 69 semanas)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study will test a study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B). REGN20423 is a study medicine that is only used in clinical studies. REGN20423 has not previously been studied in humans. The study is looking at: * What side effects REGN20423 might cause * How much REGN20423 is in the blood at different times * How well REGN20423 works in adults with atopic dermatitis * Whether the body makes antibodies against REGN20423 * How the body changes after having REGN20423, which can help researchers understand why REGN20423 works better in some people than others * What the best dose of REGN20423 is

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07527923), actualizada en jun 2026.